Treatment outcomes of concurrent chemoradiotherapy for locally advanced sinonasal squamous cell carcinoma: A single-institution study

Kim, Ji Heui; Lee, Yoon Se; Chung, Yoo‐Sam; Jang, Yong Ju; Kim, Sung‐Bae; Lee, Sangwook; Lee, Bong-Jae

doi:10.3109/00016489.2015.1061697

Cited by 13 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All 44 studies included information on survival data, with 35 (n = 1903) reporting on 5-year OS. 4,6-8,10,11,14-18,23-55 The weighted mean overall 5-year OS in this review was 54.5% (range, 18%-75%). Five-year OS data available on all patients undergoing surgery, open and endoscopic surgery, no surgery, radiation, surgery alone, surgery and RT, CT, and CT and RT are reported in Table 3 .…”

Section: Resultsmentioning

confidence: 72%

Prognostic Factors and Outcomes of De Novo Sinonasal Squamous Cell Carcinoma: A Systematic Review and Meta‐analysis

Nguyen¹,

Risbud²,

Birkenbeuel³

et al. 2021

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Objective To review overall survival (OS), recurrence patterns, and prognostic factors of de novo sinonasal squamous cell carcinoma (DN-SCC). Data Sources PubMed, Scopus, OVID Medline, and Cochrane databases from 2006 to December 23, 2020. Review Methods The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Articles were required to report either recurrence patterns or survival outcomes of adults with DN-SCC. Case reports, books, reviews, meta-analyses, and database studies were all excluded. Results Forty-one studies reported on survival or recurrence outcomes. The aggregate 5-year OS was 54.5% (range, 18%-75%) from 35 studies (n = 1903). Patients undergoing open surgery were more likely to receive radiation therapy and present at an advanced stage compared to those receiving endoscopic surgery (all P < .001). Advanced T stage, presence of cervical nodal metastases, maxillary sinus primary site, and negative human papillomavirus (HPV) status were all correlated with significantly worse 5-year OS. Direct meta-analysis of 8 studies demonstrated patients with surgery were more likely to be alive at 5 years compared to those who did not receive surgery (odds ratio, 2.26; 95% CI, 1.48-3.47; P < .001). Recurrence was reported in 628 of 1471 patients from 26 studies (42.7%) with an aggregate 5-year locoregional control rate of 67.1% (range, 50.4%-93.3%). Conclusion This systematic review and meta-analysis suggests that the 5-year OS rate for DN-SCC may approach 54.5% and recurrence rate approaches 42.7%. In addition, various tumor characteristics including advanced T stage, positive nodal status, maxillary sinus origin, and negative HPV status are all associated with decreased survival.

show abstract

Section: Resultsmentioning

confidence: 72%

Prognostic Factors and Outcomes of De Novo Sinonasal Squamous Cell Carcinoma: A Systematic Review and Meta‐analysis

Nguyen¹,

Risbud²,

Birkenbeuel³

et al. 2021

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“… 13 Conversely, Kim et al indicated no difference in survival rates between patients who underwent surgery and postoperative radiotherapy and those who received CCRT—including locoregional recurrence–free, distant metastasis–free, disease-specific, and overall survival. 14 …”

Section: Discussionmentioning

confidence: 99%

“…13 Conversely, Kim et al indicated no difference in survival rates between patients who underwent surgery and postoperative radiotherapy and those who received CCRT-including locoregional recurrence-free, distant metastasis-free, disease-specific, and overall survival. 14 There has been a consensus regarding multidrug therapy for several types of cancer, including leukemia, lymphoma, colon cancer, and lung cancer, considering action and resistance to drugs. One of the crucial reasons for failure of cancer treatment is the development of drug resistance by cancer cells; hence, multidrug therapy is a promising approach to prevent cancer cell resistance.…”

Section: Discussionmentioning

confidence: 99%

Preliminary Study of Chemoradiotherapy Using Modified Docetaxel, Cis‐diaminodichloroplatinum, and 5‐Fluorouracil for Sinonasal Squamous Cell Carcinoma

et al. 2021

View full text Add to dashboard Cite

Objective To examine the safety and efficacy of concomitant chemoradiotherapy using a modified TPF regimen (docetaxel + cisplatin + 5-fluorouracil) in patients with advanced sinonasal squamous cell carcinoma (SNSCC). Study Design Retrospective study. Setting Tertiary center (university hospital). Methods Seven patients with previously untreated T3-T4 SNSCC were enrolled. They underwent radiotherapy once daily (total dose, 70 Gy) with 2 courses of concomitant 120-hour infusion of 5-fluorouracil (600 mg/m2/d), docetaxel (50 mg/m2, day 2), and cisplatin (60 mg/m2, day 2) Results Grade 4 leukopenia, grade 4 neutropenia, and grade 3 lymphopenia were observed in 1, 3, and 4 patients, respectively. Grade 4 creatinine elevation was observed in 1 patient. However, other grade 3 or 4 adverse events were not common. Complete response was obtained in all patients. At 60 months there was 85.7% disease-free survival and 100% overall. Conclusion Concomitant chemoradiotherapy with a modified TPF regimen may be feasible and effective in patients with advanced SNSCC.

show abstract

“…Kreppel et al [ 18 ] published the results of 53 patients with locally advanced squamous cell carcinoma of the maxillary sinus and found a complete response rate of 21% after neoadjuvant CRT; higher response rates were seen with the use of cisplatin (10 of 11 patients with a complete response received cisplatin) [ 18 ]. However, despite the encouraging complete response rate, it is clear from other series of CRT alone that even with the administration of higher doses, a significant number of patients will ultimately fail loco-regionally [ 19 - 21 ]. Despite this, previous studies suggest patients who achieve a complete response after therapy appear to be in a better prognostic group than patients with a partial or stable response [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration

et al. 2016

View full text Add to dashboard Cite

PurposeWe sought to determine if organ preservation (OP) with neoadjuvant chemoradiation (CRT) was feasible in patients with sinonasal cancer determined to require exenteration.Materials and MethodsTwenty patients were determined to require exenteration for definitive treatment from 2005 to 2014. Fourteen patients underwent OP and 6 patients received exenteration with adjuvant CRT. Exenteration free survival (EFS), locoregional control (LRC), progression-free survival (PFS), and overall survival (OS) were estimated.ResultsFive patients (36%) receiving OP had complete disease response at time of surgery. With a median follow-up of 18.8 months, EFS was 62% at 2 years for patients undergoing OP. At 2 years, there were no significant differences in LRC, PFS or OS (all all p > 0.050) between the groups. Less grade 3 or greater toxicity was seen in patients undergoing OP (p = 0.003). Visual function was preserved in all patients undergoing OP.ConclusionFor patients with sinonasal cancer, OP may avoid exenteration, offering similar disease control and improved toxicity.

show abstract

Treatment outcomes of concurrent chemoradiotherapy for locally advanced sinonasal squamous cell carcinoma: A single-institution study

Abstract: The locoregional recurrence-free, distant metastasis-free, disease-free, disease-specific, and overall survival rates did not differ between PORT and CCRT groups. In addition, there were no significant differences in incidence rates of acute and chronic toxicities between the two groups.

Cited by 13 publications

References 15 publications

Prognostic Factors and Outcomes of De Novo Sinonasal Squamous Cell Carcinoma: A Systematic Review and Meta‐analysis

Prognostic Factors and Outcomes of De Novo Sinonasal Squamous Cell Carcinoma: A Systematic Review and Meta‐analysis

Preliminary Study of Chemoradiotherapy Using Modified Docetaxel, Cis‐diaminodichloroplatinum, and 5‐Fluorouracil for Sinonasal Squamous Cell Carcinoma

Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration

Contact Info

Product

Resources

About